Michael DeMane is finally a CEO.
The former chief operating officer at Medtronic Inc. (NYSE: MDT), once thought to be a top candidate to lead the world’s largest medical device firm, recently joined Lanx Inc. as chairman and CEO.
The company, based in Broomfield, Colo., makes devices for spinal surgeries. Investors include Chicago Growth Partners, Goldman Sachs Private Equity Opportunities Fund, Noro-Moseley Partners and Oakwood Medical Investors.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
“Lanx has established considerable momentum based on an impressive product portfolio and pipeline,” DeMane said in a statement. Founders “Michael Fulton, Jeffrey Thramann and their team have built a company with a responsive, solutions-oriented culture, while maintaining a high level of ethics and integrity. We expect to continue our commitment to those values in our mission to build a world-class spine company over the long-term.”
Interesting that DeMane’s statement focused on Lanx’s ” high level of ethics and integrity.” DeMane joined Medtronic in 1999 when the company bought spine firm Sofamor Danek. He served as president of Medtronic’s spine division where “he was instrumental in building one of the largest global spine franchises and his tenure was marked by a period of substantial new product flow and rapid revenue growth,” the Lanx release said.
Yet DeMane’s tenure was marked by controversy. In 2006, Medtronic paid $40 million to settle a federal investigation that accused the company of making improper payments to doctors who recommended Medtronic’s spine products. The Justice Department accused Sofamor Danek of paying kickbacks to doctors through “sham consulting agreements, sham royalty agreements and lavish trips to desirable locations.”
The episode prompted Sen. Chuck Grassley (R-Iowa) to examine possible conflict-of-interest relationships between doctors and medical device companies, scrutiny that continues today.
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
In 2008, two former employees of Medtronic spine division, filed a federal whistle-blower lawsuit against the company, alleging they and more than 100 other physicians and physician groups nationally received improper payments to buy and promote “Infuse Bone Graft.” The suit also states they marketed the product for uses not approved by regulators.
Despite the legal problems, DeMane, who was promoted to COO in 2007, was thought to be a leading candidate to succeed longtime CEO Art Collins. But the job went to current CEO Bill Hawkins and DeMane eventually left Medtronic.
Since then, he has served as senior advisor to Minneapolis venture capital firm Thomas, McNerney & Partners. DeMane has also been an active investor, putting money into startups like Denali Medical II and Rotation Medical.
Partner Peter McNerney said DeMane remains an adviser to his firm.
